Leiden, The Netherlands, November 21, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed an agreement for the acquisition of Stockholm-based SBL Vaccin AB (SBL) from 3i and SEB for a total consideration of EUR 39.4 million in cash. It is expected that the acquistion will be completed on Thursday, November 23, 2006.
In addition, Crucell today announced that it intends to raise EUR 80 million through the issue of new ordinary shares. The proceeds will be used to fund the acquisition of SBL, refinance the acquisition of Berna Products Corporation completed on October 2, 2006 and repay outstanding debt of Berna Biotech AG.
* SBL's main product Dukoral® is a market leading oral vaccine
against cholera, which will further expand and strengthen Crucell's
travel vaccines franchise
* The acquisition further strengthens Crucell's sales organization
* SBL generated approximately EUR 25.2 million in revenues in 2005,
EBIT amounted to EUR 2.6 million and cash flow was EUR 0.6 million
* Through Q3 of 2006 SBL generated EUR 17.6 million in revenues, EUR 0.5
million in EBIT and EUR 2.7 million in cash flow
SBL is a fully integrated independent Swedish biotechnology company employing 120 people. SBL's main product is Dukoral®, an oral vaccine which offers protection against cholera and is registered in more than 50 countries excluding the US. Dukoral® is also registered in the same countries (excluding the EU and Australia) to protect against ETEC (travelers' diarrhea). Sales have increased by more than 60% since 2004. In 2005 sales exceeded EUR 14 million (SEK 125 million).
In addition, SBL is the leading sales and distribution organization for vaccines in Scandinavia. The company markets a broad range of vaccines sourced from global vaccine companies including Crucell. Revenues related to the distribution of third party products amounted to approximately EUR 11 million (SEK 100 million) in 2005.
Revenues for the nine-month period ended September 30, 2006 amount to EUR 17.6 million. EBIT for the nine months ended September 30, 2006 amount to EUR 0.5 million, compared to EUR 2.6 million for the full year 2005. The 2006 EBIT reflects seasonality and mix in revenue patterns. Cash flow for the nine-month period ended September 30, 2006 amount to EUR 2.7 million and include certain one-time payments. Cash flow for full year 2005 was EUR 0.6 million.
Crucell acquired Berna Products Corporation, now part of Crucell Vaccine Inc., in the US on October 2, 2006. The acquisition of SBL further expands Crucell's global sales reach and strengthens its sales organization through SBL's strong presence in the Scandinavian markets. Furthermore, SBL's main product, Dukoral®, strengthens Crucell's portfolio of travel vaccines, which includes Epaxal® and Vivotif®.
"The acquisitions of SBL and Berna Products Corporation both fit perfectly in our strategy to further expand our travel vaccines portfolio," said Crucell's CEO Ronald H.P. Brus. "We now have access to 'best in class' marketing & sales capabilities, which we will use to accelerate future sales growth and support new product launches."
In conjunction with the acquisition of SBL, Crucell intends to raise EUR 80 million through the issue of new ordinary shares. The proceeds of the offering will be used for:
* Funding the acquisition of SBL (EUR 39.4 million)
* Refinancing the acquisition Berna Products Corporation (EUR 14
million) including related costs
* Repayment of outstanding mortgage loans held in Berna Biotech AG
(EUR 19 million)
* Additional proceeds (net of transaction costs) will be used for
general corporate purposes
Crucell published its third quarter results on November 14, 2006 and held an Analyst Meeting on November 16, 2006. Crucell narrowed the range for its revenue guidance for the year, which it now expects to be in the EUR 140 million to EUR 150 million range. Fourth quarter revenues are expected to be strong due to strong influenza vaccine sales, which are concentrated in the fourth quarter due to the late start of the influenza season this year. Moreover, sales of its new Quinvaxem(TM) pediatric vaccine have first started in October 2006. The total decrease in cash over 2006, excluding the cash acquired in the Berna Biotech acquisition on February 22, 2006, was expected to be in the range of EUR 33 million to EUR 38 million. The Company aims to achieve cash break even in 2007.
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com.
The Securities have not been and will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No portion of the Securities will be registered, and there will be no public offering of Securities, in the United States.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).
For further information please contact:
Leonard Kruimer Paul Vermeij
Chief Financial Officer Director Investor Relations
Tel. +31 (0)71 524 8722 and Corporate Communications
firstname.lastname@example.org Tel. +31 (0)71 524 8718
Copyright © Hugin ASA 2006. All rights reserved.
Source: Crucell N.V.
>>> Discuss This Story